Craig Clifford, DVM, MS, DACVIM (Oncology), and Christine Mullin, VMD, DACVIM (Oncology), discuss the logistics and implications of immunotherapy treatments for canine oncology patients.
Christine Mullin VMD, DACVIM (Oncology)
Advertisement
A board-certified veterinary oncologist, Mullin received a VMD from the University of Pennsylvania School of Veterinary Medicine, completed an internship in small animal medicine and surgery, and pursued a 3-year residency in medical oncology. During her residency, she conducted bench top research in osteosarcoma at the Pediatric Oncology Branch of the NIH National Cancer Institute, for which she received the 2014 Most Outstanding Resident Basic Science Research award from the Veterinary Cancer Society. She has authored/coauthored multiple journal articles and book chapters.
Articles by Christine Mullin VMD, DACVIM (Oncology)
What is the difference between ELIAS Cancer Immunotherapy and traditional treatments like chemotherapy and radiation?
Assessing traditional and recently approved therapies for canine lymphoma
Advertisement
Latest Updated Articles
Treatment options for canine lymphomaPublished: June 7th 2022 | Updated:
A new tool treating canine osteosarcomaPublished: April 4th 2025 | Updated:
- What makes a patient a good ELIAS Cancer Immunotherapy candidate?
Published: May 27th 2025 | Updated:
Advertisement
Advertisement
